Servier, a global pharmaceutical Group, and X-Chem Inc., a privately held drug discovery company, have partnered to identify and develop novel small molecules for the treatment of neurological disorders.   Under the terms of the multi-target agreement, X-Chem will utilize its DNA-Encoded library (DEL) platform to identify novel small molecule leads directed towards Central Nervous System (CNS) targets of interest to Servier. The parties may further progress identified leads into protein-degradin...